

Index

- Numbers in *italics* indicate *tables, figures* and *boxes*.
- N-acylphosphatidylethanolamine (NAPE) 9–10
- Addiction Severity Index (ASI) 189
- adenylate cyclase 7
- affect regulation model of substance use 171
- alcohol
- Drinking Motives Questionnaire 173, 174, 176, 177
  - exacerbation of psychotic symptoms 169
  - motivational models for use *see* motivational models of substance use
  - see also* reasons for substance use in psychosis
- Alzheimer's disease 134
- AM-251 12
- AM-281 12
- AM-404 12
- ambivalence 193
- 'amotivational syndrome'
- components 49
  - debate about 48, 50
  - laboratory study 50
  - observational studies 48–50
  - and personality type 50
  - similarity with negative dimension of psychosis 80
- 'amfetamine psychosis' 90
- anandamide
- appetite stimulation 29
  - bioassay 8
  - biosynthesis 9–10, 130
  - chemical structure 19–20
  - CSF levels in schizophrenia 96, 132–3
  - distribution in brain 130
  - half-life 132
  - inactivation 10–11, 130
  - isolation 7–8
  - role in sleep–waking cycle 28
  - synthetic analogues 12
  - transport 130–1
- animal studies of cannabinoids
- memory effects 26–7
  - psychomotor effects 24–5
  - rewarding effects 31–2
  - self-administration 32, 33
  - withdrawal syndrome 32–3
  - see also* CB<sub>1</sub> receptor knockout mice
- anxiety effects of cannabidiol 6, 46
- anticonvulsant effects of cannabidiol 5
- antidepressant effects of Δ<sup>9</sup>-THC 45
- antipsychotic drug metabolism and cannabis 124
- antipsychotic effects of cannabidiol 6
- anxiety
- effects of cannabidiol 6, 46
  - effects of cannabis 45–6, 149–50, 149, 150
  - effects of CB<sub>1</sub> antagonists 46
- appetite effects of cannabinoids 29
- 2-arachidonoylglycerol (2-AG)
- biosynthesis 10, 130
  - chemical structure 19–20
  - CNS concentrations 130
  - entourage effect 8
  - inactivation 10–11, 130
  - isolation 8
- assessment of cannabis use in psychosis
- aspects for consideration 188, 188
  - importance of therapeutic relationship 190
  - readiness to change 190
  - reasons for use 189–90
  - summarized 191
  - tools 189–90
- association of cause and disease 103
- attentional effects of cannabis 47

**212**      **Index**

- Australian National Survey of Mental Health and Wellbeing 104
- Berkson's bias 57
- bhang 93
- bias
  - comorbidity studies 57
  - studies of long-term cannabis use 199–200
- binocular depth inversion 131
- bipolar disorder and cannabis use 56
- brain
  - CB<sub>1</sub> receptor changes in schizophrenia 133–5
  - CB<sub>1</sub> receptor distribution 20–1, 22, 25, 28, 128, 128, 129
- brain, effects of cannabinoids 19–40
  - appetite control 29
  - inhibition of neurotransmitter release 21–2, 25, 134–5
  - intoxication *see* cannabis intoxication
  - memory
    - deficits 26, 48
    - hippocampal involvement 26–8
    - recall studies 150–2
  - neocortical effects 28–9
  - psychomotor function
    - animals 24–5
    - humans 25, 47
  - interactions with other signalling systems 26
  - mechanisms 25–6
  - retrograde synaptic signalling 22–4
  - tolerance 32
- Brief Psychiatric Rating Scale (BPRS) 83
- Buschke's Selective Reminding Test, alternative versions 201, 202
- cannabidiol (CBD) 5–6, 46
- cannabinoid chemistry 3–13
  - active constituent, isolation of 3
  - cannabidiol 5–6
  - current research 12–13
  - endogenous cannabinoids 6–7
    - biosynthesis and inactivation 9–11
    - new types 8–9
    - see also* 2-arachidonoylglycerol (2AG); anandamide
- cannabinoid 'model' psychosis 155
  - see also* cannabis and psychosis, exogenous hypothesis: possible mechanisms
- cannabinoid receptor agonists 12, 19, 46
- cannabinoid receptor antagonists 12, 19–20, 21, 46
- cannabinoid receptors
  - CB<sub>1</sub> *see* CB<sub>1</sub> receptors
  - CB<sub>1</sub>A 127–8, 130
  - CB<sub>2</sub> 7, 19
  - discovery 6–7
  - non-CB<sub>1</sub> in CNS 12, 128, 130
- cannabinoid/opioid synergism 31–2
- cannabinoids, synthetic 11–12
- cannabinol 3
- cannabis
  - early therapeutic use 2–3
  - as gateway to harder drugs 111
  - and mental illness, historical overview 1–3
  - trends in use (USA) 115, 115
  - withdrawal 32–3, 198–9
- Cannabis Amount Used and Symptom Evaluation (CAUSE) 189
- cannabis intoxication
  - actions on emotional behaviour 31
  - correlation with regional cerebral blood flow 30–1
  - dopamine release 31
  - mediation via CB<sub>1</sub> receptors 30
  - rewarding effects in animals 31–2
  - subjective experience *see* psychomimetic effects of cannabis
- 'cannabis psychosis' 89–100
  - biological plausibility 96
  - case reports 91–2
  - controlled clinical studies 92
    - 'cannabis psychosis'/schizophrenia patients 92–3
    - psychosis in cannabis users/non-users 93–4
  - debate over existence 96–7
  - epidemiological studies 91
    - drug use and psychotic experiences 95
    - limitation of 95
    - prevalence of symptoms in drug users 95
    - time trends in schizophrenia 95–6
  - ethically acceptable studies 90
  - evidence needed to infer cause 89–90
  - hypothesis 89
  - rarity of 97
- cannabis and psychosis, exogenous hypothesis 142
  - hypothesis outlined 142
  - pharmacological study of  $\Delta^9$ -THC
    - study conditions 144–5
    - data analysis 145

**213**      **Index**

- effects on distractibility and vigilance 152–3, 153
- effects on recall 150–2, 151, 152
- effects on verbal fluency 152, 153
- induction of anxiety and panic 149, 150, 149–50
- induction of negative symptoms and euphoria 148, 149, 148–9
- induction of perceptual alterations 147, 148, 147–8
- induction of positive symptoms 145–7, 146
- study participation effects 153–4
- summary of findings 154
- interpretation of findings 154–5
- possible mechanisms 156
  - dopaminergic 156–9
  - GABAergic 158, 159–60
  - glutamatergic 159
- review of published studies
  - laboratory-based pharmacological studies 143–4
  - limitations of naturalistic studies 143
- Cannabis sativa*, variations in  $\Delta^9$ -THC content 41
- cannabis use and depression 54–74
  - antidepressant effects of cannabis 45
  - cannabis as cause of depression 55
  - lack of clinical attention 54
  - limitations of the research 65–6
    - measurement of cannabis use 66
    - measurement of depression 66–7
  - reasons for the association 57–60
    - cannabis causes depression 60, 68
    - depression causes cannabis use 60–1
    - shared risk factors 61, 68
- review of evidence
  - cross-sectional surveys 62
  - effects of cannabis on mood 61
- review of evidence, longitudinal studies 62
  - cannabis use and later depression 62–4, 65–6
  - depression and later cannabis use 64–5
- study designs 67
  - genetically informative 67–8
  - longitudinal 67
- study samples
  - clinical 55–6, 57
  - convenience 56–7, 67
  - general population 57–9, 67, 68
- Cannabis Use Effect Survey (CUES) 189
- caudate putamen (C-P)
  - CB<sub>1</sub> density 134
  - dopamine transporter levels 135
- causation
  - concept defined 101
  - defining criteria 103
  - necessary and sufficient causes
    - causal pie model 102, 101–2
    - illustrative example 102
  - strengths of component causes 113
- CB<sub>1</sub> receptor knockout mice
  - absence of DSI 23
  - cannabinoid/opioid interaction studies 33–4
  - hippocampal function studies 28
  - impaired extinction of aversive memories 28
  - locomotor activity 25–6
  - schizophrenia symptoms 96
- CB<sub>1</sub> receptors
  - in Alzheimer's disease 134
  - changes in schizophrenia 133–5
  - distribution in brain 20–1, 22, 25, 28, 128, 128, 129
  - gene polymorphisms in schizophrenia 137
    - 1359A/G polymorphism 136–7
    - triplet repeat 136
  - in Huntington's disease 133, 134
  - inhibition of neurotransmitter release 134–5
  - mediation of cognitive effects of
    - cannabinoids 159–60
  - molecular biology 127–8
  - mRNA distribution 128–30
- CB<sub>1A</sub> receptors 127–8, 130
- CB<sub>2</sub> receptors 7, 19
- change, readiness to 190
- charas 2
- cholecystokinin 27, 28
- clinical bias 57
- cognitive deficits, conditions causing 145–7
- cognitive effects of cannabis 29, 48, 158–60
  - see also* residual cognitive effects of long-term cannabis
- cognitive motivational model 171–2, 174, 179, 181
- Community Assessment of Psychic Experiences (CAPE) 77, 79
- comorbidity
  - artefactual 57
  - defined 55
  - true 57
- conditioned place preference paradigm 31
- confounding 103

- Cooper's DMQ *see* Drinking Motives Questionnaire (DMQ)
- CP-55940 20, 22
- cultural divergence
  - of cannabis users 201
  - Navajo American study 202, 201–2
- cytokine suppression by cannabidiol 5
- DA *see* specific dopamine entries
- dagga 6
- dependence on cannabis
  - attitude change regarding 32
  - and opiate dependence 33–4
  - self-administration in animals 32, 33
  - withdrawal syndrome studies 32–3, 198–9
- depolarization-induced suppression of excitation (DSE) 23–4
- depolarization-induced suppression of inhibition (DSI) 22–3, 24
- direction and causation 103
- distractibility, effects of  $\Delta^9$ -THC 153, 152–3
- Donovan, M. 2
- dopamine D2 signalling in schizophrenia 133
- dopamine (DA)–cannabinoid interactions 156
  - cognitive effects 158–60
  - dopamine transporter (DAT) levels 135
  - effects of D2 receptor antagonists 44, 157, 158
  - facilitation of DA neurotransmission 31, 135–6, 156–7
  - inhibition of DA neurotransmission 157–8
  - summarized
- dorsolateral prefrontal cortex (DLPFC), CB<sub>1</sub>
  - density in schizophrenia 134
- dose–response relationships of  $\Delta^9$ -THC 43–4, 143
- Drinking Motives Questionnaire (DMQ) 173, 174, 176, 177
- driving, effects of cannabis 47
- dronabinol *see*  $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC)
- DSE (depolarization-induced suppression of excitation) 23–4
- DSI (depolarization-induced suppression of inhibition) 22–3, 24
- Dunedin Multidisciplinary Health and Development Study 107, 108–9, 110, 110, 111, 114
- Edinburgh High Risk Study 113
- EEG activity, effects of cannabis 28
- endogenous cannabinoid system
  - components 127
  - in time estimation 47
  - see also* specific components
- endogenous cannabinoid system in
  - schizophrenia 131–8
- CB<sub>1</sub> receptor gene polymorphism studies 137
  - 1359A/G polymorphism 136–7
  - triplet repeat 136
- endogenous hypothesis 142
- FAAH gene polymorphism study 137
- human CSF studies 132–3
- perceptual disturbance studies 131–2
- postmortem human brain studies
  - CB<sub>1</sub> receptor changes 133–5
  - dopamine transporter levels 135
- endogenous cannabinoids
  - biosynthesis and inactivation 9–11
  - discovery of receptors 6–7
  - new types 8–9
  - non-neuronal sources 133
  - retrograde synaptic signalling 22–4
  - see also* 2-arachidonoylglycerol (2AG); anandamide
- entourage effect 8, 155
- euphoriant effects of cannabis 42, 44–5, 149
- exogenous hypothesis of cannabis and psychosis
  - see* cannabis and psychosis, exogenous hypothesis
- Experience Sampling Method (ESM) studies 81–2
- experiences of cannabis use *see* psychomimetic effects of cannabis
- fatty acid amide hydrolase (FAAH)
  - activity 10–11
  - gene polymorphism study 137
- fatty acid amide hydrolase (FAAH) inhibitors 46
- GABA–cannabinoid interactions 25, 27, 158, 159–60
- gelastic epilepsy 45
- genetically informative research designs 67–8
- glutamate 159
- haloperidol pretreatment and  $\Delta^9$ -THC effects 44, 157, 158
- harm reduction strategies 193
- hashish intoxication, Moreau's experiments 1–2
- hibernation 12
- hippocampus

**215**      **Index**

- CB<sub>1</sub> receptors 27
  - effects of knockout/antagonists on function 27–8
  - mediation of cognitive effects of cannabinoids 159–60
  - synaptic plasticity and cannabinoids 27, 159
- HU-210 11
- HU-211 12
- HU-308 12
- Huntington's disease 133, 134
- immunohistochemical mapping of CB<sub>1</sub> receptors 20
- Indian hemp 2
- JWH-133 12
- laughter and cannabis 42, 44–5
- learning effects of  $\Delta^9$ -THC 150, 151
- 2-linoleoylglycerol (2-Lino-G) 8
- long-term depression (LTD) 25, 27, 159
- long-term potentiation (LTP) 27, 28, 159
- Ludlow, F. H. 42
- mania and cannabis use 55
- Marshall, C. R. 42
- Maudesley Addiction Profile (MAP) 189
- mediation motivational model 180–1, 181
- memory, cannabinoid effects
  - deficits 26, 48
  - hippocampal involvement 26–8
  - recall studies 150–2, 151, 152
- metanandamide 12
- 'model' psychoses
  - cannabinoid 155
  - limitations 155–6
  - uses 155
  - see also* cannabis and psychosis, exogenous hypothesis: possible mechanisms
- monkeys,  $\Delta^9$ -THC effects 3–4
- Moreau, J. J. 1–2
- morphine 3
- motivational interviewing (MI) 193
- motivational models of substance use 167, 171
  - cognitive 171–2, 174, 181
  - supporting studies 172–4
  - two-dimensional (Cooper) 173–4
- motivational models of substance use in psychosis
  - cognitive 179, 181
  - mediational 180–1, 181
  - motives as predictors of use/problems 179–80
  - supporting studies 175–80, 177, 178
  - see also* reasons for substance use in psychosis
- mRNA
  - CB<sub>1</sub> receptor 128–30
  - CB<sub>1</sub>A receptor 130
- naloxone 33
- Navajo American study 201–2, 202
- neocortical effects of cannabinoids 28–9
- Netherlands Mental Health Survey and Incidence Study (NEMESIS) 107, 108, 114
- neurotransmitters, modulation of release 21–2, 25, 134–5
- noladin ether 8, 12
- nucleus accumbens (NAc),  $\Delta^9$ -THC and DA release in 156
- oleamide 13
- opiate dependence, links with cannabinoid dependence 33–4
- opioid/cannabinoid synergism 31–2
- oral ingestion of cannabis 41
- O'Shaughnessy, W. B. 2
- Oxford–Liverpool Inventory of Feelings and Experiences 77
- palmitoylethanolamide (PEA) 13, 132
- 2-palmitoylglycerol (2-Palm-G) 8
- panic attacks 46, 150, 150
- perceptual effects of cannabis 28–9, 131–2, 147–8, 147, 148
  - see also* time perception and cannabis use
- personality and cannabis use 50, 182
- Peters *et al.* Delusion Inventory (PDI-21) 77
- peyote 201
- population attributable fraction (PAF) 115
- prefrontal cortex (PFC), cannabinoid effects 158–9
- psychomimetic effects of cannabis 41–53
  - 'amotivational syndrome' *see* 'amotivational syndrome'
  - anxiety 45–6, 149–50, 149, 150
  - cognitive *see* cognitive effects of cannabis
  - effects summarized 42, 44
  - euphoria and laughter 42, 44–5
  - experience of 'high' 30
  - factors affecting experience 41
  - historical accounts 42
  - human experiments

**216**      **Index**

- psychomimetic effects of cannabis (*cont.*)
    - dose–response relationships 43–4, 143
    - early observational study 43
    - effects of CB<sub>1</sub> blockade 44
    - role of DA 44, 157, 158
  - memory *see* memory, cannabinoid effects
  - psychomotor effects 47
    - see also* brain, effects of cannabinoids: psychomotor function
  - surveys of individuals’ experiences 42–3
  - time perception 29, 42, 47–8
    - see also* cannabis intoxication
- psychomotor function *see* brain, effects of cannabinoids: psychomotor function
- psychoses
  - amfetamine 90
  - cannabis *see* ‘cannabis psychosis’
  - controlled studies in cannabis users/non-users 93–4
  - difficulties in adaptation to symptoms 181
  - model *see* model psychoses
  - self-medication *see* self-medication hypothesis: psychoses
  - symptom exacerbation by substance use 169
  - vulnerability to 83
    - see also* cannabis and psychosis, exogenous hypothesis; motivational models for substance use in psychosis; reasons for substance use in psychosis; *specific schizophrenia entries*
- psychosis proneness in cannabis users 75–88
  - cannabis as risk factor 75, 82, 85
  - cross-sectional studies
    - dimensions of psychosis proneness 76–8
    - implications of findings 80
    - main limitation 80
    - methodological considerations 79–80
    - positive psychosis proneness 76
  - defined 75–6
  - direction of causality 80
  - further research 85
  - pre-existing psychosis vulnerability 82
    - defined 83
    - implications of findings 84
    - long-term effects of cannabis 83–4
    - short-term effects of cannabis 82–3
  - prospective studies
    - antiemetic trials 81
    - Experience Sampling Method studies 81–2
    - see also* ‘cannabis psychosis’
- R-(+)-WIN55212 128, 129
- reasons for substance use in psychosis
  - affect regulation model 171
  - assessment in individuals 189–90
  - dysfunctional beliefs 182
  - factors for consideration 166
  - importance of understanding of 166
  - investigations
    - forced-choice methods 167–8
    - hypotheses generated 170
    - open-ended questions 168–70
  - personality 50, 182
  - self-medication *see* self-medication hypothesis: psychoses
  - social affiliation 171
  - summarized 183
    - see also* motivational models of substance use
- recall *see* memory, cannabinoid effects
- receptors, cannabinoid *see* cannabinoid receptors
- referral bias 57
- regional cerebral blood flow (rCBF) in cannabis intoxication 30–1
- relapse prevention (RP) 193
- residual cognitive effects of long-term cannabis 198–210
  - and age of onset of use 206, 207
  - and lifetime duration of use 205–6, 207
  - long-term effects 199
    - current knowledge 204–5
  - problems with naturalistic studies 199
    - confounding variables 200
    - cultural divergence 201–2
    - selection/information bias 199–200
- residual effects defined 198
- short-term effects
  - current knowledge 149, 151
  - duration 143
  - withdrawal effects 143
- retrograde synaptic signalling 22–4
- Reynolds, Russell 2
- rimonabant (SR-141716A)
  - activity 19
  - anxiogenicity 46
  - appetite suppression 29
  - chemical structure 21

**217** **Index**

- induction of cannabis withdrawal 32–3
- locomotor stimulation in mice 25
- routes of administration and bioavailability 41
- schizophrenia
  - anandamide levels 96, 132–3
  - cognitive deficits 119
  - compared with ‘cannabis psychosis’ 92–3
  - dimensions 119
  - effect of cannabidiol 6
  - endogenous cannabinoid system in *see*
    - endogenous cannabinoid system in schizophrenia
  - epidemiological trends and cannabis use 95–6
  - hebephrenic 136
  - positive psychotic symptoms on cannabis use 96
  - self-medication with cannabis 123–4, 136
  - symptoms in CB<sub>1</sub> knockout mice 96
  - see also* cannabis and psychosis, exogenous hypothesis; treatment of cannabis use in psychosis
- schizophrenia, cannabis as causal factor 101–18
  - component cause 112
  - evidence for association 103–4
    - local surveys 105
    - national surveys 104–5
  - evidence for temporal priority/direction, retrospective studies 105–6
  - evidence for temporal priority/direction, prospective studies 106
    - alternative explanations of results 111–12
    - Dunedin birth cohort 107, 108–9, 110, 110, 111, 114
    - Dutch NEMESIS sample 107, 108
    - methodological issues 110–11
    - summarized 107, 112, 114
    - Swedish conscript cohort 106–8, 107, 114
  - high-risk studies 113
  - necessary or sufficient cause 112
  - strength of causal effect 113–16
- schizophrenia, cannabis effects on course 119–26
  - biological explanation 124
  - cross-sectional and retrospective studies 120
  - future studies 124
  - long-term prospective studies 122–3
  - short-term prospective studies 121, 122
    - effects on symptom dimensions 121–2
  - follow-up study 122
  - psychotic relapses 121, 123
  - vulnerability to stress 124
- Schizotypal Personality Questionnaire (SPQ) 76
- Schizotypy-A scale (STA) 76
- screening for cannabis use in psychosis
  - basic procedure 187
  - clinical correlates 187–8
  - collateral information 187
  - combined approach 187
  - importance 186
  - reasons for underdetection 186–7
  - summarized 188, 188
  - tools 187
  - urinalysis 187
- self-administration of  $\Delta^9$ -THC in animals 32, 33
- self-medication hypothesis
  - depression 60–1, 65–6
  - psychoses 80, 82–3, 170–1, 182
    - schizophrenia 123–4, 136
- service delivery models
  - integrated 191–2
  - parallel 191
  - sequential 191
  - summarized 191
- smoked cannabis 4, 41
- social adjustment and cannabis use 59, 80
- SPECT study, cannabis-induced DA
  - changes 135–6
- SR-141716A *see* rimonabant (SR-141716A)
- SR-144528 12
- Stage of Change Readiness and Treatment Eagerness Scale (SOCRATES) 190
- stearoyl ethanolamide 13
- stereoselectivity of cannabinoids 6–7
- subjective experiences of cannabis use *see*
  - psychomimetic effects of cannabis
- substance use, reasons for *see* reasons for substance use in psychosis
- Substance Use Scale for Psychosis (SUSP) 189–90
- suicidality and cannabis use 55, 56, 63
- Swedish conscript cohort studies 107, 106–8, 114
- synthetic cannabinoids 11–12
- temporal priority of cause over disease 103
- $\Delta^8$ -tetrahydrocannabinol ( $\Delta^8$ -THC) 3
- $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC)
  - antidepressant properties 45
  - appetite effects 29
  - chemical structure 19–20

**218**      **Index**

- temporal priority of cause over disease (*cont.*)
  - comparison in humans and monkeys 3–4
  - content of *Cannabis sativa* 41
  - distractibility and vigilance effects 152–3, 153
  - dose estimation difficulties 143
  - effects on DA 31, 135
  - effects on endogenous enkephalins 33
  - euphoriant effects 45
  - identification as cannabis active constituent 3
  - induction of anxiety and panic 149–50, 149, 150
  - induction of perceptual alterations 147, 148, 147–8
  - inhibition of neurotransmitter release 21–2
  - recall effects 151, 152, 150–2
  - rewarding effects in animals 31–2
  - route of administration and bioavailability 41
  - verbal fluency effects 152, 153
  - see also* cannabinoid chemistry; specific cannabis entries
- $\Delta^8$ -THC 3
- $\Delta^9$ -THC *see*  $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC)
- time perception and cannabis use 29, 42, 47–8
- tolerance to cannabis 32
- trans-theoretical model of change 190
- treatment of cannabis use in psychosis
  - approaches 192
    - 12-step 192
    - combined 192–3
    - harm reduction 193
    - motivational interviewing 193
    - relapse prevention 193
  - programmes 193–5
  - see also* assessment of cannabis use in psychosis; screening for cannabis use in psychosis; service delivery models
- twin studies, cannabis use and depression 67
- two-dimensional motivational model (Cooper) 173–4
- tyrosine hydroxylase (TH) 135
- UK National Psychiatric Morbidity Survey 104
- US National Epidemiological Catchment Area study 104
- verbal fluency,  $\Delta^9$ -THC effects 152, 153
- vigilance,  $\Delta^9$ -THC effects 152–3
- virodhamine 8
- VR1 receptors 8
- WIN55 212-2, chemical structure 19–20
- withdrawal syndrome 32–3, 198–9